Systemic Cancer Therapy
Systemic cancer therapy is the use of drugs that travel through the bloodstream to reach cancer cells throughout the body, in contrast to locoregional treatments such as surgery and radiotherapy. It groups together the major medical-oncology drug classes — cytotoxic chemotherapy, molecularly targeted agents, hormonal (endocrine) therapy, and immunotherapy — along with the principles of combining them rationally and managing their interactions.
Definition
Systemic cancer therapy comprises pharmacological treatments — administered orally or parenterally so they act systemically — that aim to kill, arrest, or otherwise control malignant cells throughout the body, encompassing cytotoxic, targeted, hormonal, and immunological drug classes.
Scope
This area orients the reader to the main modalities of drug-based cancer treatment and the biological rationale behind each. It links to detailed topics on cytotoxic chemotherapy principles, targeted therapy and kinase inhibitors, hormonal therapy, immunotherapy and checkpoint inhibitors, and combination regimens with drug interactions. It is a conceptual reference and does not provide dosing or individualized treatment recommendations.
Sub-topics
Core questions
- What distinguishes systemic from locoregional cancer treatment?
- How do the major drug classes (cytotoxic, targeted, hormonal, immunotherapeutic) differ in mechanism?
- Why are agents combined into regimens rather than given singly?
- How does tumour biology determine which systemic modality is appropriate?
Key concepts
- Systemic versus locoregional therapy
- Cytotoxic chemotherapy
- Molecularly targeted therapy
- Hormonal (endocrine) therapy
- Immunotherapy and checkpoint blockade
- Combination regimens
- Therapeutic index and dose-limiting toxicity
- Acquired drug resistance
Mechanisms
The modalities differ in what they exploit. Cytotoxic chemotherapy damages DNA or disrupts cell division, hitting rapidly proliferating cells. Targeted therapy inhibits a specific molecule — often a kinase or growth-factor receptor — on which a tumour depends. Hormonal therapy removes or blocks the hormonal signals that drive hormone-sensitive cancers. Immunotherapy, especially checkpoint blockade, releases brakes on the patient's own T cells so they attack tumour cells. The expansion from broadly cytotoxic agents toward target- and immune-directed approaches reflects a deeper understanding of the molecular hallmarks that sustain malignancy.
Clinical relevance
Systemic therapy underlies most medical-oncology practice and is frequently combined with surgery or radiotherapy. Understanding the modalities supports critical reading of oncology evidence and communication across the care team. This entry describes how these treatments are conceived and is not a guide to selecting or dosing therapy for any individual patient.
Evidence & guidelines
The evidence base spans landmark trials and reviews across the modalities — from the historical development of combination chemotherapy to pivotal trials of targeted agents and checkpoint inhibitors. Practice is organized by tumour-specific and modality-specific guidelines from bodies such as the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO); this reference does not reproduce those recommendations.
History
Modern systemic therapy began with the observation that nitrogen mustard could shrink lymphomas, followed in the mid-twentieth century by the development of antimetabolites and, critically, the principle of combining drugs to overcome resistance. Subsequent decades added hormonal therapies, then molecularly targeted agents exemplified by kinase inhibitors, and most recently immune checkpoint inhibitors, progressively shifting oncology toward biologically rational treatment.
Key figures
- Vincent T. DeVita
- Bruce A. Chabner
- Douglas Hanahan
- Robert A. Weinberg
- James P. Allison
Related topics
Seminal works
- chabner-2005
- hanahan-weinberg-2011
- ribas-wolchok-2018
Frequently asked questions
- How is systemic therapy different from chemotherapy?
- Chemotherapy (cytotoxic drugs) is one type of systemic therapy. Systemic therapy is the broader umbrella that also includes targeted agents, hormonal therapy, and immunotherapy — any drug treatment that acts throughout the body.
- Why are several drugs often used together?
- Combining agents with different mechanisms and non-overlapping toxicities can attack the tumour on multiple fronts and reduce the chance that resistant cells survive, which is the rationale behind combination regimens.